🏛️ Verified NIH Record • Updated 2026-07-22

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo (NCT06548360)

A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Incyte Corporation

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (14 items).

Location: University of Alabama At Birmingham-School of Medicine — Birmingham, Alabama

Age range: 2 Years to 11 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Diagnosis of other forms of vitiligo (eg, segmental).
  • Other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
  • Any other skin disease that, in the opinion of the investigator, would interfere with the study drug application or study assessments.
  • Prior or current use of depigmentation treatments (eg, monobenzone).
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including application of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Use of protocol-defined treatments within the indicated washout period before baseline.
  • History of treatment failure with any systemic or topical JAK inhibitor (eg, ruxolitinib, tofacitinib, baricitinib, abrocitinib, and upadacitinib) for vitiligo or any other inflammatory condition.
  • Protocol-defined clinically significant abnormal laboratory values at screening.
  • Pregnant or lactating participants or those considering pregnancy during the period of their study participation.
  • In the opinion of the investigator, unable or unlikely to comply with the application schedule and study evaluations.
  • Living with anyone participating in any current Incyte-sponsored ruxolitinib cream study.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (98 Sites)

Showing the first 25 of 98 sites.

  • University of Alabama At Birmingham-School of Medicine — Birmingham, Alabama
  • Saguaro Dermatology — Phoenix, Arizona
  • Phoenix Children'S Hospital — Phoenix, Arizona
  • Omni Dermatology — Phoenix, Arizona
  • Affiliated Dermatology — Scottsdale, Arizona
  • Banner - University Medicine Multispecialty Services Clinic — Tucson, Arizona
  • Premier Dermatology Clinical Trials Institute At Northwest Arkansas — Fayetteville, Arkansas
  • Burke Pharmaceutical Research — Hot Springs, Arkansas
  • Axon Clinical Research — Inglewood, California
  • University of California Irvine — Irvine, California
  • Vitiligo & Pigmentation Institute of Southern California — Los Angeles, California
  • Dermatology Research Associates — Los Angeles, California
  • La Universal Research Center, Inc — Los Angeles, California
  • Stanford School of Medicine — Palo Alto, California
  • Empire Clinical Research — Pomona, California
  • Peninsula Research Associates Pra — Rolling Hills Estates, California
  • Rady Children'S Hospital-San Diego — San Diego, California
  • Golden State Dermatology — Walnut Creek, California
  • Children'S Hospital Colorado — Aurora, Colorado
  • Paradigm Clinical Research Centers, Inc. — Wheat Ridge, Colorado
  • Skin Care Research, Llc — Boca Raton, Florida
  • Encore Medical Research, Llc Boynton Beach — Boynton Beach, Florida
  • Skin Care Research, Llc — Hollywood, Florida
  • Solutions Through Advanced Research, Inc — Jacksonville, Florida
  • Pediatric Skin Research Llc — Miami, Florida

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in NonSegmental Vitiligo

Explore by condition: All NonSegmental Vitiligo clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗